Alexium International Group Limited · ASX:AJX
Alexium International — Shareholder Meeting (November 2021)
11 slides from Alexium International's shareholder meeting presentation, Nov 17, 2021
Slide 1: Alexium 2021 Annual General Meeting
ALEXIUM 2021 ANNUAL GENERAL MEETING 17 November 2021 ASX: AJX
Slide 2: Disclaimer
Disclaimer To the maximum extent permitted by law, the information contained in this presentation is given without any liability whatsoever being accepted by Alexium International Group Limited (Alexium) or any of its related entities or their respective directors or officers, employees, advisors an
Slide 3: Alexium at a Glance
Alexium at a Glance An advanced materials provider of proprietary technologies for flame retardant and thermal management applications •Technology leader in textile/foam-based products for US consumer and military Analytics markets IP-driven •Patented and patent-pending technologies Products develop
Slide 4: Product Portfolio Overview
Product Portfolio Overview Building from an initial set of three products, over the past few years Alexium has significantly expanded its product portfolio to five platforms Two new platforms (highlighted in yellow in the diagram) were introduced in FY2021. Range of addressable markets have be
Slide 5: FY2021 in Review
FY2021 in Review Continued Improvements versus prior year Revenue Growth Gross Margin Operating Expenses 19.7% FY2020 FY2021 FY2020 FY2021 Revenue growth from new customers and Decrease due to product mix, H2 gross margin Headcount and travel expenses down, offset by Total Mattress Cooling System ov
Slide 6: FY2021 in Review
FY2021 in Review Deliberate and systematic changes throughout the company drive conclusive results Strong customer H1 impacted by product demand in H2 mix Operating Expenses normalising H2 benefit from improved margins/mix and stable expense All values in USD and thousands unless otherwise noted 6
Slide 7: AJX Revenue Growth Over Past Six Months
AJX Revenue Growth Over Past Six Months • From June 2021, AJX has shown Monthly Revenue (Trailing Three-Month Average) significant revenue growth $1,200 • Two key initiatives came to fruition $1,000 mid-calendar year: $800 • BioCool products fully Revenue ($USK) commercialized $600 • New mattress de
Slide 8: FY2022: Primary Areas of Revenue Growth
FY2022: Primary Areas of Revenue Growth Target Market(s) Target Market(s) Target Market(s) Mattress Mattress Mattress (FR Sock) Top-of-Bed products Body Armor Status Status Status Qualified customer preparing Qualified customer preparing Customers evaluating for commercialization for commerc
Slide 9: Key Milestones for FY2022
Key Milestones for FY2022 Optimization of FR NyCo Broader market penetration manufacturing process and of BioCool™ products in submission for military testing & bedding market evaluation Major customer has fully Complete commercialisation commercialized mattresses 1H 2H of Alexiflam® NF for FR Sock
Slide 10: FY2022: Pivotal Year for Alexium's Growth
FY2022: Pivotal Year for Alexium’s Growth Culmination of FY2018 – FY2021 Technical & Commercial Developments REVENUE DRIVERS Total mattress cooling system full commercialization – Ramp begun in 4Q FY2021, full rate in 1H FY2022 Increased Continued market penetration for BioCool™ products – First sal
Slide 11: GY ALexium
GY ALexium
Alexium International Group — Shareholder Meeting (November 2021) on 6ix